Infliximab

Therapeutic indications

Infliximab is indicated for:

Rheumatoid arthritis

Population group: only adults (18 years old or older)

Infliximab, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:

  • adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate.
  • adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn’s disease

Population group: only adults (18 years old or older)

Infliximab is indicated for:

  • treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
  • treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only adults (18 years old or older)

Infliximab is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Psoriatic arthritis

Population group: only adults (18 years old or older)

Infliximab is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

Infliximab should be administered:

  • in combination with methotrexate.
  • or alone in patients who show intolerance to methotrexate or for whom methotrexate is

contraindicated.

Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ankylosing spondylitis

Population group: only adults (18 years old or older)

Infliximab is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Psoriasis

Population group: only adults (18 years old or older)

Infliximab is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn’s disease

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Infliximab is indicated for treatment of severe, active Crohn’s disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Infliximab is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Infliximab is contraindicated in the following cases:

Tuberculosis

Tuberculosis

Sepsis

Systemic infection

Abscess

Abscess

Moderate or severe heart failure (NYHA class III/IV)

at least one of
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.